unknown
Stage
About
Fertiga develops the Aurora niPCT™, a non-invasive molecular diagnostic test analyzing cumulus cells removed during ICSI to accurately rank egg quality and improve embryo selection in IVF treatments, increasing pregnancy and live birth rates.
Explore Fertiga's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.